105 related articles for article (PubMed ID: 3119200)
1. Pharmacokinetics of continuous-infusion high-dose thiotepa.
Henner WD; Shea TC; Furlong EA; Flaherty MD; Eder JP; Elias A; Begg C; Antman K
Cancer Treat Rep; 1987 Nov; 71(11):1043-7. PubMed ID: 3119200
[TBL] [Abstract][Full Text] [Related]
2. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
[TBL] [Abstract][Full Text] [Related]
4. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation.
Kletzel M; Kearns GL; Wells TG; Thompson HC
Bone Marrow Transplant; 1992 Aug; 10(2):171-5. PubMed ID: 1525606
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
9. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
[TBL] [Abstract][Full Text] [Related]
10. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
13. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
16. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer.
Lazarus HM; Reed MD; Spitzer TR; Rabaa MS; Blumer JL
Cancer Treat Rep; 1987; 71(7-8):689-95. PubMed ID: 3111687
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
[TBL] [Abstract][Full Text] [Related]
18. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
19. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.
Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J
Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
